Penetration of idarubicin into malignant brain tumor tissue

Journal of Neuro-Oncology

Volumn 44, Issue 1, 1999, Pages 65-69

  Boogerd, W ^a,b   Tjahja, I S ^a   Van De Sandt, M M ^a   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Brain metastasis; Glioma; Idarubicin

Indexed keywords

ANTHRACYCLINE; IDARUBICIN; IDARUBICINOL;

ARTICLE; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN METASTASIS; BREAST CANCER; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG PENETRATION; GLIOBLASTOMA; GLIOMA; HUMAN; METABOLITE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIBIOTICS, ANTINEOPLASTIC; ASTROCYTOMA; BRAIN NEOPLASMS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; GLIOBLASTOMA; HUMANS; IDARUBICIN;

EID: 0032743206     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006335517191     Document Type: Article

References (20)

1. Zülch KJ: Brain Tumors. Their Biology and Pathology. New York, Springer 1986
2. Berger MS, Leibel SA, Bruner JM: Primary central nervous system tumors of the supratentorial compartment. In: Levin VA, ed. Cancer in the Nervous System Chestchill Livingstone, New York 1996, pp 57-127
3. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993
4. Chang CH, Horton J, Schoenfeld D, Salazer O, Peter-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy with combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997-1007, 1983
5. Brada M, Thomas DGT, Bleehen NM, Roberts JT, Senanayake F, Abram P, Lantos PL, Moss TH, Ironside JW, Whaley JB, Stenning SP: Medical research council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG). Proc ASCO 17: 400a (abstract), 1998
6. Mahaley MS: Neuro-oncology index and review: adult primary brain tumors. J Neuro-Oncol 11: 85-147, 1991
7. Posner JB: Neurologic Complication of Cancer. Davis, Philadelphia 1995
8. Boogerd W, Dalesio O, Bais EM, Van der Sande JJ: Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69: 972-980, 1992
9. Kristensen CA, Kristjansen PEG, Hansen H: Systemic chemotherapy of brain metastases from small cell lung cancer. J Clin Oncol 10: 1498-1502, 1992
10. Kaaijk P, Troost D, de Boer OJ, Van Amstel P, Bakker PJM, Leenstra S, Bosch DA: Daunorubicin and adriamycin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas. Br J Cancer 74: 187-193, 1996
11. Von Holst H, Knochenhamer E, Blomgren H, Collins VP, Ehr L, Lindquist M, Noren G, Peterson C: Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir 104: 13-16, 1990
12. Kuffel MJ, Reid JM, Ames MA: Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemoth Pharmacol 30: 51-57, 1992
13. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM: Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. Cancer Res 50: 6525-6528, 1990
14. Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guarraldi M, Benedetti MS, Efthymiopoulos C, Pannuti F: Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 30: 307-316, 1992
15. Beijnen JH, Neef C, Bouma J, Paalman ACA, Underberg WJM: Analysis of 4-demethoxy-daunorubicin and metabolites in plasma and urine. Chem Pharm Bull 36: 3503-3511, 1988
16. Feig SA, Ames MA, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, Bleyer WA, Harris RE: Comparison of idarubicin to daunomycin in a randomized multiding treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse. Med Pediatr Oncol 27: 605-614, 1996
17. Lopez M, Contegiacomo A, Vici P, Dello-Ioio C, DiLauro L, Pagliarulo C, Carpano S, Giannerelli D, DePlacidio S, Fazio S, Bianco AR: A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 64: 2431-2436, 1989
18. Martoni A, Plana E, Gueraldi M, Cilenti G, Farris A, Saccani F, Becchi G, Pannuti F: Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 47: 427-432, 1990
19. Case DC, Hayes DM, Gerber M, Gams R: Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Proceed Am Assoc Cancer Res 31: 1146, 1990
20. Chisesi T, Capnist G, DeDominicis E, Dini E: A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 24: 681-690, 1988